When a global biopharma company set aggressive milestones for a high-stakes Phase III vaccine trial, complexity across geographies, supply chains, and regulatory requirements threatened to delay first patient in (FPI). Through the Accelerator™ Drug Development framework, Thermo Fisher Scientific helped align timelines, resolve quality agreement discrepancies, and streamline execution—enabling five weeks of time savings and on-time startup across more than 170 sites worldwide. Discover how collaborative oversight turned a high-risk timeline into a repeatable success.